Civitas Therapeutics generated positive top line results in a Phase I trial of CVT-301, its inhaled version of L-dopa to treat Parkinson's disease-related tremors. The drug, which is ingested through a hand-held inhaler, reached sufficient levels that support "its therapeutic potential," the Chelsea, MA, company said. Civitas' test on healthy volunteers was also shown to be safe and well-tolerated at many different dose levels, the company said. Civitas believes that the 40-year-old L-dopa drug will better maintain peak L-dopa plasma concentration than the more common oral delivery, which is not absorbed right away and can lead to variable plasma levels as well as debilitating Parkinson's symptoms. A grant from The Michael J. Fox Foundation for Parkinson's Research helped cover the cost. Release | Article